Core Points - GENFIT's NIS2+® has been included in the European Clinical Practice Guidelines for managing metabolic dysfunction-associated steatotic liver disease (MASLD), marking a significant recognition of its role in identifying at-risk patients [1][2][3] - The guidelines were developed collaboratively by the European Association for the Study of the Liver (EASL), the European Association for the Study of Diabetes (EASD), and the European Association for the Study of Obesity (EASO) [2] - NIS2+® is the only blood-based diagnostic tool mentioned for detecting at-risk MASH, emphasizing its importance in clinical practice as liver biopsy becomes less common due to its invasiveness [4] Company Overview - GENFIT is a late-stage biopharmaceutical company focused on rare and life-threatening liver diseases, with a diverse R&D portfolio targeting conditions like Acute-on-Chronic Liver Failure (ACLF) and cholangiocarcinoma [7][8] - The company has a strong history in liver disease research and has developed diagnostic technologies, including NIS2+®, which is designed to detect at-risk MASH among patients with metabolic risk factors [6][8] - GENFIT is listed on both Nasdaq and Euronext, and has received significant investment, including an 8% stake acquisition by Ipsen in 2021 [8]
GENFIT: New EASL-EASD-EASO Clinical Practice Guidelines for MASLD Include NIS2+® as Key Tool for Detecting At-Risk MASH